Activity of the Epipodophyllotoxin VP-16 in the Treatment of Combination Chemotherapy-Resistant Non-Hodgkin Lymphoma
- 1 January 1978
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 5 (3), 203-209
- https://doi.org/10.1002/ajh.2830050305
Abstract
Twenty patients with several histologic subtypes of non-Hodgkin lymphoma who had become resistant to combination chemotherapy were treated with a five-day course of the epipodophyllotoxin VP-16. Of 19 evaluable patients, 8 (42%) responded to treatment with 1 complete response and 7 partial responses. The median duration of response was 5.5 months. Seven of the responders had a diffuse lymphoma and 1 had a nodular lymphoma. Of the responders who had diffuse histiocytic lymphoma (DHL), diffuse mixed lymphoma (DML), and diffuse undifferentiated lymphoma (DUL)–the more aggressive histologies in the Rappaport classification–6 of 13 (46%) evaluable patients responded to therapy. Responses were seen in node-dominant, skin-dominant, and marrow-dominant disease. Toxicity was mainly hematopoietic, 53% of patients experiencing leukopenia (<2, 000 cells per cu mm) and 68% of patients experiencing thrombocytopenia (<100, 000 platelets per cu mm). There were two deaths attributable to profound leukopenia with sepsis. The activity of VP-16 in patients who have previously been extensively treated with multiple drugs including vincristine supports its activity in the lymphomas and suggests its lack of cross-resistance with vincristine. The inclusion of VP-16 in primary treatment protocols in the diffuse lymphomas should be considered.Keywords
This publication has 8 references indexed in Scilit:
- VM 26 and VP 16–213: A comparative analysisCancer, 1977
- Cyclophosphamide, vincristine, and prednisone (CVP) versus adriamycin, bleomycin, and prednisone (ABP) in stage IV non-Hodgkin's lymphomasMedical and Pediatric Oncology, 1977
- A clinical trial of the oral form of 4′-demethyl-epipodophyllotoxin-β-D ethylidene glucoside (NSC 141540) VP 16–213Cancer, 1975
- Total body irradiation (TBI) as primary therapy for advanced lymphosarcomaCancer, 1975
- Two epipodophyllotoxin derivatives, VM 26 and VP 16213, in the treatment of leukemias, hematosarcomas, and lymphomasCancer, 1974
- Neurotoxicity of Commonly Used Antineoplastic AgentsNew England Journal of Medicine, 1974
- Epipodophyllotoxin VP 16213 in Treatment of Acute Leukaemia--Haematosarcoma and Solid TumoursBMJ, 1973
- The Similarity of the Effect of Podophyllin and Colchicine and Their Use in the Treatment of Condylomata AcuminataScience, 1946